What it is
Werner syndrome helicase (WRN) is a synthetic lethal target in cancers with microsatellite instability (MSI): a protein these cancer cells depend on to survive, although other cells do not. In part 1 of an ongoing first-in-human phase 1 trial, 88 patients with advanced solid tumors showing MSI and/or deficient DNA mismatch repair received escalating doses of RO7589831 (VVD-133214), a first-in-class inhibitor that binds WRN covalently, once daily (150 mg), twice daily (150 to 1,000 mg) or three times daily (200 to 600 mg). The primary aims were safety, tolerability and choosing the dose and schedule for phase 2. Adverse events that arose during treatment were mostly grade 1 or 2 among those seen in at least 10% of patients; the most common were nausea (54.5% of patients), diarrhea (43.2%), fatigue (39.8%), anemia (37.5%, grade 3 or higher in 11.4% of patients) and vomiting (30.7%). Three patients (3.4%) stopped the drug because of adverse events, no adverse event was fatal (grade 5), and the one dose-limiting toxicity was grade 2 nausea at 600 mg three times daily; per the protocol, a maximum tolerated dose was not identified.
Why it matters
In a phase 1 trial of a first-in-class WRN inhibitor, 7 of 66 evaluable patients with MSI tumors (10.6%) had confirmed partial responses and 49 (74.2%) had disease control (shrinking or stable tumors), both secondary end points; the responses lasted a median of at least 10.2 months. Median progression-free survival was 6.7 months (95% CI, 4.1 to 8.5) and median overall survival 17.6 months (95% CI, 17.6 to not estimable). The 150-mg and 600-mg twice-daily doses were chosen for dose optimization, and the authors say these data suggest that the drug has a manageable safety profile and warrants further clinical testing.
Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.
Filed underGenetic factors in colorectal cancer, PARP inhibition in cancer therapy, DNA Repair Mechanisms